Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging.
Amyloid plaques are one of the pathological hallmarks of Alzheimer's disease (AD). The visualization of amyloid plaques in the brain is important to monitor AD progression and to evaluate the efficacy of therapeutic interventions. Our group has developed several contrast agents to detect amyloid plaques in vivo using magnetic resonance microimaging (μMRI) in AD transgenic mice, where we used intra-carotid mannitol to enhance blood-brain barrier (BBB) permeability. In the present study, we used ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, chemically coupled with Aβ1-42 peptide to detect amyloid deposition along with mannitol for in vivo μMRI by femoral intravenous injection. A 3D gradient multi-echo sequence was used for imaging with a 100μm isotropic resolution. The amyloid plaques detected by T2*-weighted μMRI were confirmed with matched histological sections. Furthermore, two different quantitative analyses were used. The region of interest-based quantitative measurement of T2* values showed contrast-injected APP/PS1 mice had significantly reduced T2* values compared to wild-type mice. In addition, the scans were examined with voxel-based morphometry (VBM) using statistical parametric mapping (SPM) for comparison of contrast-injected AD transgenic and wild-type mice. The regional differences seen in VBM comparing USPIO-Aβ1-42 injected APP/PS1 and wild-type mice correlated with the amyloid plaque distribution histologically, contrasting with no differences between the two groups of mice without contrast agent injection in regions of the brain with amyloid deposition. Our results demonstrated that both approaches were able to identify the differences between AD transgenic mice and wild-type mice, after injected with USPIO-Aβ1-42. The feasibility of using less invasive intravenous femoral injections for amyloid plaque detection in AD transgenic mice facilitates using this method for longitudinal studies in the pathogenesis of AD.
Department of Neurology, New York University School of Medicine, New York, NY 10016, USA.
Jing
J
Yang
Youssef Zaim
YZ
Wadghiri
Dung Minh
DM
Hoang
Wai
W
Tsui
Yanjie
Y
Sun
Erika
E
Chung
Yongsheng
Y
Li
Andrew
A
Wang
Mony
M
de Leon
Thomas
T
Wisniewski
D000544:Alzheimer Disease / Q000150:complications / Q000175:diagnosis*; D016229:Amyloid beta-Peptides; D000818:Animals; D003287:Contrast Media; D003911:Dextrans; D016503:Drug Delivery Systems / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010446:Peptide Fragments; D058225:Plaque, Amyloid / Q000150:complications / Q000175:diagnosis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D016229:Amyloid beta-Peptides; D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); C097921:ferumoxtran-10
J Neurooncol. 1992 Jan;12(1):33-46
1541977
Magn Reson Med. 2003 Aug;50(2):293-302
12876705
Methods Mol Biol. 2005;299:365-79
15980617
Age (Dordr). 2007 Sep;29(2-3):87-96
19424834
Am J Pathol. 2001 Aug;159(2):439-47
11485902
Mt Sinai J Med. 2010 Jan-Feb;77(1):17-31
20101719
J Cell Mol Med. 2010 Apr;14(4):914-21
20569276
Neurobiol Dis. 2006 Apr;22(1):199-208
16337798
Neurosurgery. 1995 May;36(5):965-70
7791989
Prog Brain Res. 2009;180:72-96
20302829
Brain Res. 1991 Nov 1;563(1-2):311-4
1786545
Biomaterials. 2010 Oct;31(30):7748-57
20673685
Behav Neurol. 2009;21(1):117-28
19847050
J Magn Reson Imaging. 2006 Sep;24(3):530-6
16892201
Methods Mol Biol. 2011;686:213-27
21082373
Crit Care Resusc. 2009 Jun;11(2):151-4
19485880
Nat Clin Pract Neurol. 2005 Dec;1(2):96-105
16932505
Radiology. 1990 May;175(2):494-8
2326475
Magn Reson Med. 2004 Sep;52(3):538-44
15334572
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
10860804
J Magn Reson Imaging. 2009 May;29(5):997-1007
19388095
Mt Sinai J Med. 2010 Jan-Feb;77(1):32-42
20101720
Science. 2002 Jul 19;297(5580):353-6
12130773
J Neurosci Res. 2008 Sep;86(12):2784-91
18615702
J Cell Mol Med. 2009 Mar;13(3):412-21
19374683
Brain Res Bull. 2010 Apr 5;81(6):600-4
20026388
Neurobiol Aging. 2010 Oct;31(10):1679-89
19027991
Nat Med. 1998 Jan;4(1):97-100
9427614
Neuroscience. 2009 Feb 6;158(3):1151-60
18651996
Nat Rev Neurol. 2010 Feb;6(2):108-19
20140000
J Biol Chem. 1996 May 3;271(18):10602-6
8631862
Magn Reson Med. 2004 Dec;52(6):1263-71
15562496
BMC Med. 2009 Feb 19;7:7
19228370
Cell Mol Neurobiol. 2000 Apr;20(2):217-30
10696511
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14079-84
10570201
Cell. 2005 Feb 25;120(4):545-55
15734686
Neuroimage. 2008 Apr 1;40(2):482-494
18234520
Gene Ther. 2009 Nov;16(11):1340-52
19587708
Magn Reson Med. 2005 Mar;53(3):607-13
15723413
J Nucl Med. 1994 Nov;35(11):1831-41
7965166
Neurobiol Aging. 2008 Jun;29(6):836-47
17291630
Invest Radiol. 2009 Jun;44(6):336-42
19661843
J Magn Reson Imaging. 2006 Nov;24(5):1011-7
17036339
NMR Biomed. 2007 May;20(3):343-51
17451178
Neurobiol Dis. 2009 Jan;33(1):20-7
18930824
Neurobiol Aging. 2006 Jun;27(6):835-47
16023262
J Cereb Blood Flow Metab. 2010 Jan;30(1):15-35
19756021
Nat Rev Neurol. 2010 Feb;6(2):78-87
20139997
Am J Pathol. 2000 Jul;157(1):331-9
10880403
Exp Neurol. 2002 Feb;173(2):183-95
11822882
Magn Reson Imaging. 2009 Oct;27(8):1163-74
19249168
Magn Reson Med. 2004 Apr;51(4):794-8
15065253
Mt Sinai J Med. 2009 Apr;76(2):119-28
19306369
Magn Reson Med. 2009 May;61(5):1158-64
19253386
Am J Pathol. 2004 Sep;165(3):937-48
15331417
Neuroimage. 2010 Jun;51(2):586-98
20206704
Magn Reson Med. 2009 May;61(5):1148-57
19253389